{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:43:58Z","timestamp":1790311438294,"version":"4.1.0"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,3,20]],"date-time":"2019-03-20T00:00:00Z","timestamp":1553040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2019.00207","type":"journal-article","created":{"date-parts":[[2019,3,20]],"date-time":"2019-03-20T04:40:47Z","timestamp":1553056847000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["The Cannabinoid CB1 Antagonist TM38837 With Limited Penetrance to the Brain Shows Reduced Fear-Promoting Effects in Mice"],"prefix":"10.3389","volume":"10","author":[{"given":"Vincenzo","family":"Micale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Drago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia K.","family":"Noerregaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian E.","family":"Elling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten T.","family":"Wotjak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,3,20]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"4786","DOI":"10.1073\/pnas.1218573110","article-title":"Activation of the sympathetic nervous system mediates hypophagic and anxiety-like effects of CB\u2081 receptor blockade","volume":"110","author":"Bellocchio","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"4751","DOI":"10.1016\/j.bmcl.2013.06.066","article-title":"Peripherally restricted CB1 receptor blockers","volume":"23","author":"Chorvat","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1016\/S0140-6736(07)61721-8","article-title":"Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials","volume":"370","author":"Christensen","year":"2007","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/j.1365-2710.2010.01164.x","article-title":"An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity","volume":"36","author":"Christopoulou","year":"2011","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1172\/JCI17725","article-title":"The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis","volume":"112","author":"Cota","year":"2003","journal-title":"J. Clin. Invest."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/978-3-642-17214-4_4","article-title":"Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes","volume":"203","author":"Di Marzo","year":"2011","journal-title":"Handb. Exp. Pharmacol."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1038\/ncomms2035","article-title":"Biocompatibility of a genetically encoded calcium indicator in a transgenic mouse model","volume":"3","author":"Direnberger","year":"2012","journal-title":"Nat. Commun."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"pyw068","DOI":"10.1093\/ijnp\/pyw068","article-title":"The CB1 neutral antagonist AM4113 retains the therapeutic efficacy of the inverse agonist rimonabant for nicotine dependence and weight loss with better psychiatric tolerability","volume":"19","author":"Gueye","year":"2016","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1046\/j.1460-9568.2002.02192.x","article-title":"The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety","volume":"16","author":"Haller","year":"2002","journal-title":"Eur. J. Neurosci."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.brainres.2013.06.011","article-title":"Lack of interaction of endocannabinoids and 5-HT(3) neurotransmission in associative fear circuits of the amygdala: evidence from electrophysiological and behavioural experiments","volume":"1527","author":"H\u00f6felmann","year":"2013","journal-title":"Brain Res."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1111\/j.1601-183X.2009.00512.x","article-title":"Endocannabinoids render exploratory behaviour largely independent of the test aversiveness: role of glutamatergic transmission","volume":"8","author":"Jacob","year":"2009","journal-title":"Genes Brain Behav."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.nlm.2012.04.008","article-title":"Cannabinoid CB1 receptor deficiency increases contextual fear memory under highly aversive conditions and long-term potentiation in\u00a0vivo","volume":"98","author":"Jacob","year":"2012","journal-title":"Neurobiol. Learn. Mem."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1517\/17460441.2011.608063","article-title":"Cannabinoid 1 G protein-coupled receptor (periphero-)neutral antagonists: emerging therapeutics for treating obesity-driven metabolic disease and reducing cardiovascular risk","volume":"6","author":"Janero","year":"2011","journal-title":"Expert Opin. Drug Discovery"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1101\/lm.86104","article-title":"Nonassociative learning processes determine expression and extinction of conditioned fear in mice","volume":"11","author":"Kamprath","year":"2004","journal-title":"Learn. Mem."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"6677","DOI":"10.1523\/JNEUROSCI.0153-06.2006","article-title":"Cannabinoid CB1 receptor mediates fear extinction via habituation-like processes","volume":"26","author":"Kamprath","year":"2006","journal-title":"J. Neurosci."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/j.1601-183X.2008.00463.x","article-title":"Endocannabinoids mediate acute fear adaptation via glutamatergic neurons independently of corticotropin-releasing hormone signaling","volume":"8","author":"Kamprath","year":"2009","journal-title":"Genes Brain Behav."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/j.1748-1716.2011.02402.x","article-title":"CB1 receptor antagonists: new discoveries leading to new perspectives","volume":"205","author":"Kirilly","year":"2012","journal-title":"Acta Physiol."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1111\/bcp.12141","article-title":"Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837\u00a0in healthy subjects","volume":"76","author":"Klumpers","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00213-009-1506-7","article-title":"The future of endocannabinoid-oriented clinical research after CB1 antagonists","volume":"205","author":"Le Foll","year":"2009","journal-title":"Psychopharmacology"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1007\/s00213-015-3917-y","article-title":"2-AG promotes the expression of conditioned fear via cannabinoid receptor type 1 on GABAergic neurons","volume":"232","author":"Llorente-Berzal","year":"2015","journal-title":"Psychopharmacology"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/nature00839","article-title":"The endogenous cannabinoid system controls extinction of aversive memories","volume":"418","author":"Marsicano","year":"2002","journal-title":"Nature"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"7109","DOI":"10.1523\/JNEUROSCI.1054-12.2012","article-title":"Bimodal control of fear-coping strategies by CB\u2081 cannabinoid receptors","volume":"32","author":"Metna-Laurent","year":"2012","journal-title":"J. Neurosci."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1038\/mp.2012.145","article-title":"Neutral antagonism at the cannabinoid 1 receptor: a safer treatment for obesity","volume":"18","author":"Meye","year":"2013","journal-title":"Mol. Psychiatry"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.pharmthera.2012.12.002","article-title":"Endocannabinoid system and mood disorders: priming a target for new therapies","volume":"138","author":"Micale","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"ref25","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/978-1-4939-2294-9_5","article-title":"Role of the endocannabinoid system in depression: from preclinical to clinical evidence","volume-title":"Cannabinoid modulation of emotion, memory, and motivation.","author":"Micale","year":"2015"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jpsychires.2017.02.002","article-title":"Extinction of avoidance behavior by safety learning depends on endocannabinoid signaling in the hippocampus","volume":"90","author":"Micale","year":"2017","journal-title":"J. Psychiatr. Res."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1590\/S1516-44462009000200012","article-title":"The psychiatric side-effects of rimonabant","volume":"31","author":"Moreira","year":"2009","journal-title":"Rev. Bras. Psiquiatr."},{"key":"ref28","first-page":"39","article-title":"TM38837\u2013a novel second generation peripheral selective CB1 receptor antagonist with efficacy and potency in rodent obesity models equal to brain-penetrant CB1 antagonist rimonabant","volume-title":"20th Annual Symposium of the International Cannabinoid Research Society 2010.","author":"Noerregaard","year":"2010"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"4990","DOI":"10.1523\/JNEUROSCI.6038-09.2010","article-title":"Dissociation of within- and between-session extinction of conditioned fear","volume":"30","author":"Plendl","year":"2010","journal-title":"J. Neurosci."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1038\/npp.2012.123","article-title":"Biphasic effects of cannabinoids in anxiety responses: CB1 and GABAB receptors in the balance of GABAergic and glutamatergic neurotransmission","volume":"37","author":"Rey","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.neuroscience.2011.11.057","article-title":"Fear relief-toward a new conceptual frame work and what endocannabinoids gotta do with it","volume":"204","author":"Riebe","year":"2012","journal-title":"Neuroscience"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/0014-5793(94)00773-X","article-title":"SR141716A, a potent and selective antagonist of the brain cannabinoid receptor","volume":"350","author":"Rinaldi-Carmona","year":"1994","journal-title":"FEBS Lett."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/0024-3205(96)00085-9","article-title":"Characterization and distribution of binding sites for [3H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain","volume":"58","author":"Rinaldi-Carmona","year":"1996","journal-title":"Life Sci."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1038\/s41598-018-20078-w","article-title":"New role of phenothiazine derivatives as peripherally acting CB1 receptor antagonizing anti-obesity agents","volume":"8","author":"Sharma","year":"2018","journal-title":"Sci. Rep."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.drudis.2018.01.029","article-title":"Peripheral modulation of the endocannabinoid system in metabolic disease","volume":"23","author":"Shrestha","year":"2018","journal-title":"Drug Discov. Today"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s11154-011-9167-3","article-title":"Peripheral effects of the endocannabinoid system in energy homeostasis: adipose tissue, liver and skeletal muscle","volume":"12","author":"Silvestri","year":"2011","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"ref37","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1038\/sj.npp.1301476","article-title":"The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats","volume":"33","author":"Sink","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.pbb.2010.03.011","article-title":"The CB1 inverse agonist AM251, but not the CB1 antagonist AM4113, enhances retention of contextual fear conditioning in rats","volume":"95","author":"Sink","year":"","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.euroneuro.2009.11.002","article-title":"Potential anxiogenic effects of cannabinoid CB1 receptor antagonists\/inverse agonists in rats: comparisons between AM4113, AM251, and the benzodiazepine inverse agonist FG-7142","volume":"20","author":"Sink","year":"","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref40","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/syn.21721","article-title":"Low brain CB1 receptor occupancy by a second generation CB1 receptor antagonist TM38837\u00a0in comparison with rimonabant in nonhuman primates: a PET study","volume":"68","author":"Takano","year":"2014","journal-title":"Synapse"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.cmet.2012.07.002","article-title":"Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance","volume":"16","author":"Tam","year":"2012","journal-title":"Cell Metab."},{"key":"ref42","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ejim.2018.01.009","article-title":"The therapeutic potential of targeting the peripheral endocannabinoid\/CB1 receptor system","volume":"49","author":"Tam","year":"2018","journal-title":"Eur. J. Intern. Med."},{"key":"ref43","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3389\/fnbeh.2011.00049","article-title":"The dopamine and cannabinoid interaction in the modulation of emotions and cognition: assessing the role of cannabinoid CB1 receptor in neurons expressing dopamine D1 receptors","volume":"5","author":"Terzian","year":"2011","journal-title":"Front. Behav. Neurosci."},{"key":"ref44","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1111\/ejn.12561","article-title":"Cannabinoid receptor type 1 receptors on GABAergic vs. glutamatergic neurons differentially gate sex-dependent social interest in mice","volume":"40","author":"Terzian","year":"2014","journal-title":"Eur. J. Neurosci."},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S0140-6736(05)66374-X","article-title":"Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study","volume":"365","author":"Van Gaal","year":"2005","journal-title":"Lancet"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1038\/oby.2011.69","article-title":"Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist\/inverse-agonist therapies","volume":"19","author":"Ward","year":"2011","journal-title":"Obesity"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.nlm.2012.04.009","article-title":"Increased levels of conditioned fear and avoidance behavior coincide with changes in phosphorylation of the protein kinase B (AKT) within the amygdala in a mouse model of extremes in trait anxiety","volume":"98","author":"Yen","year":"2012","journal-title":"Neurobiol. Learn. Mem."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2019.00207\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,20]],"date-time":"2019-03-20T04:40:49Z","timestamp":1553056849000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2019.00207\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,20]]},"references-count":47,"alternative-id":["10.3389\/fphar.2019.00207"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2019.00207","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,20]]},"article-number":"207"}}